Breast Cancer
Conditions
Brief summary
The goal of this clinical trial is to develop an innovative web-based dance movement therapy (DMT) training platform and assess short-term outcomes before and after its implementation in women with breast cancer Is the DMT training platform comprehensibility and acceptability among patients? Is the DMT training platform acceptability, usability, and feasibility among healthcare providers? Does the DMT training platform have effects on alexithymia and frailty among patients? Researchers will compare experimental to a control (a a conventional care program) to see if DMT training platform works to treat severe asthma. Participants will: receive an orientation on the web-based DMT program before chemotherapy, along with a single face-to-face traditional education session on physical activity . complete training sessions three times per week, with each session lasting at least 70 min.
Interventions
OTHERweb-based dance movement therapy training intervention
Patients in the experimental group received an orientation on the web-based DMT program before chemotherapy, along with a single face-to-face traditional education session on physical activity. Participants were encouraged to complete training sessions three times per week, with each session lasting at least 70 min. Each DMT training session was divided into four components: (1) Proprioception; (2)Warm-up and stretching techniques; (3) Main part; (4) Relaxation.
Sponsors
Chin-Tsung Shen
Ministry of Science and Technology, Taiwan
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
20 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients who were about to start chemotherapy were recruited from a hospital in Taipei, Taiwan
Exclusion criteria
* major illness (e.g., heart failure, stroke, blindness) or a pre-existing mental disorder * a history of limb amputation * prior participation in dance therapy before their breast cancer diagnosis
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Alexithymia | one year (2024/08/01-2025/07/31) | Alexithymia was assessed using the Chinese version of the Toronto Alexithymia Scale (TAS), a self-reported outcome measure \[30-31\]. The TAS consists of 20 items covering three key domains: difficulty in identifying and discriminating emotional cues, difficulty in verbally expressing emotions and feelings, and externally oriented thinking. Each item was rated on a 5-point Likert scale, ranging from 1 to 5, resulting in a total score range of 20 to 100, with higher scores indicating greater alexithymia. |
| Frailty | one year ( 2024/08/01-2025/07/31). | A breast cancer comprehensive frailty scale (BCCFS) was developed to assess frailty across three domains: deterioration in body function and mobility, negative emotional states, and cognitive impairment. The BCCFS comprises 16 items and has demonstrated strong psychometric properties, with a Cronbach's alpha of 0.91, indicating excellent internal consistency, and a test-retest reliability coefficient of 0.60 \[32\]. The validity and reliability of the BCCFS have been well established. Responses to each item were recorded on a five-point Likert scale, with higher scores indicating greater perceived frailty. |
Countries
Taiwan
Outcome results
None listed